Villejuif

• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Recruiting
  2025-524056-63-00 1 2026-06-05 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• A Study to Learn about the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive Stage Sma … Recruiting
  2025-523522-41-00 10 2026-06-01 Extensive-Stage Small Cell Lung Cancer
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2025-521327-67-00 4 2026-04-13 Metastatic Castration-Resistant Prostate Cancer
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V … Recruiting
  2025-521966-91-00 4 2026-03-31 Refractory Metastatic Breast Cancer with Liver Dominant Disease
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting
  2024-519622-20-00 1 2026-02-27 Advanced Solid Tumors Harboring RAS Mutation(S)
• A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. Recruiting
  2024-520353-21-00 3 2026-02-24 Myeloproliferative Neoplasms
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting
  2022-501607-27-00 7 2026-01-06 Relapsed or refractory B-cell Non-Hodgkin lymphoma
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 1 2025-11-26 KRAS Altered Advanced or Metastatic Solid Tumors
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 Hormone receptor positive breast cancer
• An Early Phase Clinical Trial to Evaluate COM701 in Relapsed Platinum Sensitive Ovarian Cancer (PSOC) Recruiting
  2025-521125-33-00 9 2025-09-05 Ovarian Cancer
• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult P … Recruiting
  2023-505479-56-00 1 2025-07-30 Follicular lymphoma (FL)

Showing 73–96 of 978 trials